ClinicalTrials.gg
RecruitingNCT07705737Updated Nov 4, 2026

Rademikibart IV for Acute Asthma and COPD Exacerbation

A Phase 2 interventional study of Rademikibart in Asthma Acute and COPD Exacerbation Acute, sponsored by Connect Biopharm LLC. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 4, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
925th of 1,353
40 · median 100
Started
2026
with 53 others
Phase 2
292 of 1,695
22 open now
Primary completion
2026-12
later than 42 of 183 live
Registered
1,678th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 925th largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 54 that started in 2026, is one of 292 in phase 2, reaches primary completion later than 42 of the 183 other live ones, and was the 1,678th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Read the detailed description

A phase 2, open-label, single-arm trial to assess the efficacy of a single 300 mg dose of rademikibart administered as a 2-minute IV infusion (IV push) on lung function in participants with asthma or COPD with type 2 inflammation who require an urgent healthcare visit for the treatment of acute exacerbation.

03

Conditions studied

  • Asthma Acute
  • COPD Exacerbation Acute

Keywords

  • Acute exacerbation
  • Asthma
  • Asthma exacerbation
  • CBP-201
  • Rademikibart
  • Connect Biopharma
  • COPD exacerbation
  • COPD acute
  • COPD
  • COPD flare
  • Asthma attack
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Asthma cohort

  • Body weight of ≥40 kg and ≤45 kg/m2 at SV1a.
  • Physician-diagnosed asthma
  • Currently receiving treatment with low, medium, to high dose ICS in combination with at least 1 additional asthma controller medication.
  • Must have experienced at least 1 asthma exacerbation requiring the use of systemic .
  • Participants in a stable condition, must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
  • Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.
  • Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation.
  • Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.
  • ≥30% predicted.

Exclusion Criteria - Asthma cohort

  • Regular use of medication.
  • Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension.
  • Current or former smoker, with a smoking history of ≥5 pack-years if \<30 years old or ≥10 pack-years if ≥30 years old
  • and other pulmonary disease other than asthma.
  • Known or suspected history of immunosuppression.
  • History of known immunodeficiency disorder or or C.
  • History of alcohol abuse and/or drug abuse.
  • Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix or other treated with apparent success with curative therapy.
  • Female participant who is pregnant, lactating or breast-feeding.
  • Recent receipt of any marketed nonbiologic drug that modulates type 2 cytokines.
  • Recent receipt of any marketed biologic drug or any biologic for asthma or other diseases.
  • Recent live, attenuated vaccinations or planned live, attenuated vaccinations during the trial.
  • Participants that have been recently treated with bronchial thermoplasty.
  • Recent receipt of any investigational nonbiologic drug.
  • A recent chest X-ray or computed tomography with findings that are inconsistent for an asthmatic population.

Inclusion Criteria - COPD cohort

  • Body weight of ≥45 kg and BMI ≤45 kg/m2
  • Physician-diagnosed COPD
  • Must have experienced at least 1 COPD exacerbation requiring the use of systemic corticosteroids.
  • Participants in a stable condition must have a historical peripheral blood eosinophil count of ≥250 cells/μL and/or FeNO ≥ 25 ppb.
  • Current or former smoker with a history of smoking of ≥10 pack-years.
  • Current acute COPD exacerbation requiring an urgent healthcare visit for treatment.
  • Peripheral blood eosinophil count of ≥300 cells/μL as part of the assessment of the index acute COPD exacerbation.
  • Requires systemic corticosteroids as standard of care treatment in the urgent healthcare setting for the current acute COPD exacerbation.

Exclusion Criteria - COPD cohort

  • Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to approximately 12 weeks or 5 half-lives, whichever is longer.
  • Current diagnosis or a history of asthma, according to the Global Initiative for Asthma; or participants with a current diagnosis or history of Asthma COPD Overlap Syndrome.
  • Other respiratory disorders that might compromise the safety of the participant or affect the interpretation of the results.
  • Unstable ischemic heart disease, cardiomyopathy, heart failure, uncontrolled hypertension. Cardiac arrhythmias including paroxysmal atrial fibrillation.
  • or stroke \<6 months from Screening Visit; hospitalization for any cardiovascular or cerebrovascular event \<6 months from Screening Visit.
  • Known or suspected history of immunosuppression.
  • History of known immunodeficiency disorder or hepatitis B or C.
  • History of alcohol abuse and/or drug abuse.
  • Recent history of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success.
  • Chronic treatment with long-term oxygen therapy or nocturnal oxygen therapy required for >15 hours a day.
  • Participants on long-term macrolide.
  • Current acute COPD exacerbation for which SoC was started >48 hours prior to Screening.
  • A recent chest X-ray or computed tomography scan reveals evidence of clinically significant abnormalities or pulmonary infection.
  • Female participant who is pregnant, lactating or breast-feeding.
  • Receipt of any marketed nonbiologic drug that modulates type 2 cytokines 30 days or 5 half-lives prior to SV1b, whichever is longer.
  • Receipt of any marketed or any investigational biologic for COPD or other diseases within 16 weeks or 5 half-lives, whichever is longer.
  • Live, attenuated vaccinations within 4 weeks prior to screening or planned live, attenuated vaccinations during the trial.

The above inclusion and exclusion criteria are not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rademikibart

    Drug: Rademikibart

Interventions

  • DrugRademikibart

    Single 300 mg dose as a 2-minute IV push

    Also known as: CBP-201

06

What researchers measure

Primary outcomes

  1. Change from baseline in post-BD FEV1

    Time frame: 1 week

Secondary outcomes

  1. Change from baseline in post-BD FEV1 at scheduled timepoints

    Time frame: Days 1, 2, 3, 14, 28, and 42

  2. Incidence of treatment-emergent adverse events

    Time frame: 42 days

07

Study locations

2 of 3 sites recruiting
  • Columbus Clinical Services, LLC
    Miami, Florida 33135, United States
    Active, not recruiting

    Not enrolling at this site.

  • Pharmax Research of South Florida, Inc.
    Miami, Florida 33175, United States
    Recruiting
  • Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory
    St Louis, Missouri 63110, United States
    Recruiting
08

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
Show 2 sites
  • Columbus Clinical Services, LLC · Miami, United StatesNot yet recruiting→Active, not recruiting
  • Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory · St Louis, United StatesNot yet recruiting→Recruiting
Show site
  • Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory · St Louis, United States
across 4 updates, Oct 16, 2026 – Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Columbus Clinical Services, LLC · Miami, United StatesContact removed c•••@connectpharm.com · •••7990
Nov 4, 2026
Show all 4 updates
  1. Nov 4, 2026
    Columbus Clinical Services, LLC is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Columbus Clinical Services, LLC · Miami, United StatesContact removed c•••@connectpharm.com · •••7990
  2. Oct 27, 2026
    Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory is now Recruiting
  3. Oct 22, 2026
    1 site added
    Show site
    • Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory · St Louis, United States
  4. Oct 16, 2026
    Columbus Clinical Services, LLC is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07705737
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Aug 21, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Radha Adivikolanu
Contact
clinical209@connectpharm.com
213-522-7990

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion